Clinical efficacy research of docetaxel, cisplatin and 5 -fluorouracil adjuvant chemotherapy for esophageal carcinoma
10.13699/j.cnki.1001-6821.2015.24.005
- VernacularTitle:多西他赛联合顺铂及氟尿嘧啶对食管癌辅助化疗的临床疗效研究
- Author:
Cai-Hua YU
1
;
Zhi-Hong MA
Author Information
1. 湖州中心医院 心胸外科
- Keywords:
chemotherapy;
esophageal carcinoma;
lymph node metastasis;
prognosis
- From:
The Chinese Journal of Clinical Pharmacology
2015;(24):2387-2389
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effects of postoperative adjuvant chemotherapy with docetaxel +cisplatin +5 -fluorouracil ( DCF) on the long term prognosis in esophageal cancer patients with lymph node metastasis.Methods One hundred and nine patients with squamous cell carcinoma were divided into control group ( n =58 ) and treatment group ( n=51).Control group was given surgery alone.Treatment group was received postoperative DCF therapy, 500 mg? m -2 5 -fluorouracil on days 1-4, 60 mg? m-2 docetaxel on day 1 and 60 mg? m-2 cispla-tin on day 1.The efficacy of DCF treatment was investigated in patients divided according to the number of metastatic lymph nodes, which was divided into N1 cases ( n=68 ) and N2 cases ( n=41 ) .The disease-free, overall survival and adverse drug reactions were compared between the groups.Results The disease -free and overall survival were 45.54%and 51.23%, respectively, in the control group and 48.58%and 54.08%, respectively, in the treatment group.These differences were not considered to be statistically significant ( P>0.05 ) .Although there were no significant differences in disease-free and overall survival between the treatment and control group in N1 cases, both disease-free and overall survival were found to be better in the treatment group (38.65%and 42.10%, respectively) compared to those in the control group (25.03%and 28.58%, respectively) in N2 cases (P<0.05). The incidence of adverse drug reactions in the treatment group was 17.65% ( 9/51 ) .Conclusion Therefore, postoperative adjuvant chemotherapy with DCF was shown to improve disease-free and overall survival in moderate lymph node metastasis -positive cases ( N2 ) , suggesting that the DCF regimen may be effective as postoperative adjuvant chemotherapy for patients with lymph node metastasis from esophageal cancer.
